Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Appl Biochem Biotechnol ; 194(10): 4930-4945, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35674922

ABSTRACT

The most prevalent malignancy among women is breast cancer. Phytochemicals and their derivatives are rapidly being recognized as possible cancer complementary therapies because they can modify signaling pathways that lead to cell cycle control or directly alter cell cycle regulatory molecules. The phytochemicals' poor bioavailability and short half-life make them unsuitable as anticancer drugs. Applying PLGA-PEG NPs improves their solubility and tolerance while also reducing drug adverse effects. According to the findings, combining anti-tumor phytochemicals can be more effective in regulating several signaling pathways linked to tumor cell development. The point of the study was to compare the anti-proliferative impacts of combined artemisinin and metformin on cell cycle arrest and expression of cyclin D1 and apoptotic genes (bcl-2, Bax, survivin, caspase-7, and caspase-3), and also hTERT genes in breast cancer cells. T-47D breast cancer cells were treated with different concentrations of metformin (MET) and artemisinin (ART) co-loaded in PLGA-PEG NPs and free form. The MTT test was applied to assess drug cytotoxicity in T47D cells. The cell cycle distribution was investigated using flow cytometry and the expression levels of cyclin D1, hTERT, Bax, bcl-2, caspase-3, and caspase-7, and survivin genes were then determined using real-time PCR. The findings of the MTT test and flow cytometry revealed that each state was cytotoxic to T47D cells in a time and dose-dependent pattern. Compared to various state of drugs (free and nano state, pure and combination state) Met-Art-PLGA/PEG NPs demonstrated the strongest anti-proliferative impact and considerably inhibited the development of T-47D cells; also, treatment with nano-formulated forms of Met-Art combination resulted in substantial downregulation of hTERT, Bcl-2, cyclin D1, survivin, and upregulation of caspase-3, caspase-7, and Bax, in the cells, as compared to the free forms, as indicated by real-time PCR findings. The findings suggested that combining an ART/MET-loaded PLGA-PEG NP-based therapy for breast cancer could significantly improve treatment effectiveness.


Subject(s)
Alkylmercury Compounds , Antineoplastic Agents , Artemisinins , Breast Neoplasms , Carbanilides , Ethylmercury Compounds , Heterocyclic Compounds , Metformin , Nanoparticles , Trimethyltin Compounds , Antineoplastic Agents/chemistry , Apoptosis , Artemisinins/pharmacology , Artemisinins/therapeutic use , Benzalkonium Compounds/pharmacology , Benzalkonium Compounds/therapeutic use , Benzoflavones/pharmacology , Benzoflavones/therapeutic use , Breast Neoplasms/metabolism , Carbanilides/pharmacology , Carbanilides/therapeutic use , Caspase 3/genetics , Caspase 7 , Cell Line, Tumor , Cell Proliferation , Cyclin D1/genetics , Cyclin D1/metabolism , Cyclin D1/pharmacology , Ethylmercury Compounds/pharmacology , Ethylmercury Compounds/therapeutic use , Female , Heterocyclic Compounds/pharmacology , Humans , Metformin/pharmacology , Metformin/therapeutic use , Methacholine Compounds , Nanoparticles/chemistry , Oximes/pharmacology , Oximes/therapeutic use , Plasmalogens/pharmacology , Plasmalogens/therapeutic use , Sulfonylurea Compounds/pharmacology , Sulfonylurea Compounds/therapeutic use , Survivin/pharmacology , Survivin/therapeutic use , Trimethyltin Compounds/pharmacology , bcl-2-Associated X Protein
2.
J Cataract Refract Surg ; 48(10): 1175-1182, 2022 10 01.
Article in English | MEDLINE | ID: mdl-35383648

ABSTRACT

PURPOSE: To investigate the effects of combining oxygen supplementation with enhanced UV-A light and increased riboflavin permeability in improving the efficacy of epithelium-on crosslinking (epi-on CXL). SETTING: Private eye clinic in Brisbane, Queensland, Australia. DESIGN: Retrospective single-center nonrandomized uncontrolled longitudinal cohort case series. METHODS: Transepithelial CXL was performed on keratoconic eyes. Applications of an oxygen goggle and pulsed UV-A irradiation (1 second on, 1 second off) were used to enhance oxygen kinetics during epi-on CXL. Additional procedural modifications included the use of benzalkonium chloride and high UV-A irradiance level (30 mW/cm 2 ) to improve the stromal bioavailability of riboflavin and UV-A. The main efficacy outcomes were the changes in mean corrected distance visual acuity (CDVA) and safety over 12 months. Additional refractive and keratometry (K) outcomes were also observed. RESULTS: 53 eyes (38 patients) were included in this study. 12 months postoperatively, mean CDVA improved from a mean of 0.18 ± 0.2 at baseline to 0.07 ± 0.1 logMAR ( P < .0001). No statistically significant change was observed in maximum K (Kmax) and mean K, which were respectively 51.7 ± 5.8 diopters (D) and 46.4 ± 3.85 D at baseline and 51.2 ± 5.7 D ( P = .152) and 46.0 ± 3.84 D ( P = .06) 12 months postoperatively. Only 3 eyes experienced an increase of more than 2 D in Kmax; however, none of these eyes experienced a CDVA loss. There were no reported infections, corneal scarring, or other severe adverse effects. CONCLUSIONS: Performing supplemental oxygen epi-on CXL with accelerated, pulsed UV-A irradiation in conjunction with riboflavin permeability enhancers resulted in improved CDVA ( P < .0001) and stable keratometry up to 12 months postoperatively with a good safety profile.


Subject(s)
Keratoconus , Photochemotherapy , Benzalkonium Compounds/therapeutic use , Collagen/therapeutic use , Corneal Topography , Cross-Linking Reagents/therapeutic use , Humans , Keratoconus/drug therapy , Oxygen/therapeutic use , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Prospective Studies , Retrospective Studies , Riboflavin/therapeutic use , Ultraviolet Rays
3.
J Ocul Pharmacol Ther ; 37(10): 556-564, 2021 12.
Article in English | MEDLINE | ID: mdl-34610257

ABSTRACT

Purpose: To investigate the influence of benzalkonium chloride (BAK) on ocular surface disease (OSD) in glaucoma patients receiving ocular-hypotensive agent. Methods: Patients were randomized to receive BAK-containing latanoprost (Xalatan) or preservative-free bimatoprost (Lumigan PF). Intraocular pressure (IOP), basal Schirmer's test, noninvasive keratograph tear-breakup time (TBUT), conjunctival redness score (R score), OSD index (OSDI), and corneal Oxford staining were recorded and compared between the 2 groups at 1-month and 4-month visits. The influence of BAK was analyzed by a generalized estimating equation model. Results: We enrolled 74 and 76 eyes treated with latanoprost and bimatoprost, respectively. The IOP decreased in both groups, although greater reduction was observed for latanoprost (13.95 vs. 15.42 mmHg, P = 0.0264). There was a significantly negative association between tear flow and latanoprost use (ß = -0.763, P = 0.0243). The first and average TBUT did not show intergroup differences, but the area with unstable tear film increased with latanoprost use and showed marginal significance at 4-month visit (9.33% vs. 5.94% P = 0.055). In both groups, OSDI decreased, whereas Oxford stain increased over time, and R scores showed improvement after transient increase in the first month. The bimatoprost group had significantly worse conjunctival hyperemia, whereas a negative association with conjunctival hyperemia was revealed for latanoprost use (R score-bulbar nasal: ß = -0.045, P = 0.0423). Conclusions: BAK-containing latanoprost was associated with decreased tear secretion and may be associated with tear-film instability, whereas bimatoprost was associated with worse conjunctival hyperemia. Ocular surface side effects should be considered when prescribing BAK-containing medication to glaucoma patients.


Subject(s)
Benzalkonium Compounds/therapeutic use , Bimatoprost/therapeutic use , Glaucoma/drug therapy , Latanoprost/therapeutic use , Ophthalmic Solutions/therapeutic use , Preservatives, Pharmaceutical/therapeutic use , Adult , Aged , Benzalkonium Compounds/adverse effects , Bimatoprost/adverse effects , Comorbidity , Conjunctivitis/chemically induced , Female , Humans , Intraocular Pressure/drug effects , Latanoprost/adverse effects , Male , Middle Aged , Ophthalmic Solutions/adverse effects , Preservatives, Pharmaceutical/adverse effects , Prospective Studies , Tears/drug effects
4.
Adv Wound Care (New Rochelle) ; 10(1): 13-23, 2021 01.
Article in English | MEDLINE | ID: mdl-32496980

ABSTRACT

Significance: Biofilms in vivo are small densely packed aggregations of microbes that are highly resistant to host immune responses and treatment. They attach to each other and to nearby surfaces. Biofilms are difficult to study and identify in a clinical setting as their quantification necessitates the use of advanced microscopy techniques such as confocal laser scanning microscopy. Nonetheless, it is likely that biofilms contribute to the pathophysiology of chronic skin wounds. Reducing, removing, or preventing biofilms is thus a logical approach to help clinicians heal chronic wounds. Recent Advances: Wound care products have demonstrated varying degrees of efficacy in destroying biofilms in in vitro and preclinical models, as well as in some clinical studies. Critical Issues: Controlled studies exploring the beneficial role of biofilm eradication and its relationship to healing in patients with chronic wounds are limited. This review aims to discuss the mode of action and clinical significance of currently available antibiofilm products, including surfactants, dressings, and others, with a focus on levels of evidence for efficacy in disrupting biofilms and ability to improve wound healing outcomes. Future Directions: Few available products have good evidence to support antibiofilm activity and wound healing benefits. Novel therapeutic strategies are on the horizon. More high-quality clinical studies are needed. The development of noninvasive techniques to quantify biofilms will facilitate increased ease of research about biofilms in wounds and how to combat them.


Subject(s)
Biofilms/drug effects , Biofilms/radiation effects , Wound Healing/drug effects , Wound Healing/radiation effects , Wound Infection/drug therapy , Wound Infection/radiotherapy , Animals , Anti-Infective Agents, Local/therapeutic use , Bandages , Benzalkonium Compounds/therapeutic use , Biguanides/therapeutic use , Disinfectants/therapeutic use , Honey , Humans , Hypochlorous Acid/therapeutic use , Iodophors/therapeutic use , Low-Level Light Therapy/methods , Surface-Active Agents/therapeutic use , Ultrasonic Therapy/methods
5.
Pain ; 160(2): 307-321, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30412056

ABSTRACT

Ocular pain is a core symptom of inflammatory or traumatic disorders affecting the anterior segment. To date, the management of chronic ocular pain remains a therapeutic challenge in ophthalmology. The main endogenous opioids (enkephalins) play a key role in pain control but exhibit only transient analgesic effects due to their rapid degradation. The aim of this study was to explore the antinociceptive and anti-inflammatory effects of topical administration of PL265 (a dual enkephalinase inhibitor) on murine models of corneal pain. On healthy corneas, chronic PL265 topical administration did not alter corneal integrity nor modify corneal mechanical and chemical sensitivity. Then, on murine models of corneal pain, we showed that repeated instillations of PL265 (10 mM) significantly reduced corneal mechanical and chemical hypersensitivity. PL265-induced corneal analgesia was completely antagonized by naloxone methiodide, demonstrating that PL265 antinociceptive effects were mediated by peripheral corneal opioid receptors. Moreover, flow cytometry (quantification of CD11b+ cells) and in vivo confocal microscopy analysis revealed that instillations of PL265 significantly decreased corneal inflammation in a corneal inflammatory pain model. Chronic PL265 topical administration also decreased Iba1 and neuronal injury marker (ATF3) staining in the nucleus of primary sensory neurons of ipsilateral trigeminal ganglion. These results open a new avenue for ocular pain treatment based on the enhancement of endogenous opioid peptides' analgesic effects in tissues of the anterior segment of the eye. Dual enkephalinase inhibitor PL265 seems to be a promising topical treatment for safe and effective alleviation of ocular pain and inflammation.


Subject(s)
Cornea/pathology , Enzyme Inhibitors/administration & dosage , Inflammation/drug therapy , Pain/drug therapy , Propionates/administration & dosage , Administration, Topical , Animals , Anti-Infective Agents, Local/therapeutic use , Benzalkonium Compounds/therapeutic use , Capsaicin/toxicity , Cornea/drug effects , Corneal Injuries/chemically induced , Corneal Injuries/complications , Disease Models, Animal , Hyperalgesia/physiopathology , Inflammation/chemically induced , Lipopolysaccharides/toxicity , Male , Mice , Mice, Inbred C57BL , Naloxone/toxicity , Narcotic Antagonists/toxicity , Pain/etiology , Pain Threshold/drug effects , Sensory System Agents/toxicity , Trigeminal Ganglion/metabolism , Trigeminal Ganglion/pathology
6.
Nanomedicine (Lond) ; 12(10): 1177-1185, 2017 May.
Article in English | MEDLINE | ID: mdl-28447896

ABSTRACT

AIM: To develop NB-201, a nanoemulsion compound, as a novel microbicidal agent against methicillin-resistant Staphylococcus aureus (MRSA) infection, which is a common threat to public health but with limited therapeutic options. MATERIALS & METHODS: NB-201 was tested in in vitro and in vivo murine and porcine models infected with MRSA. RESULTS: Topical treatment of MRSA-infected wounds with NB-201 significantly decreased bacterial load and had no toxic effects on healthy skin tissues. NB-201 attenuated neutrophil sequestration in MRSA-infected wounds and inhibited epidermal and deep dermal inflammation. The levels of proinflammatory cytokines were reduced in NB-201-treated MRSA-infected wounds. CONCLUSION: NB-201 can greatly reduce inflammation characteristic of infected wounds and has antimicrobial activity that effectively kills MRSA regardless of the genetic basis of antibiotic resistance.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Benzalkonium Compounds/therapeutic use , Methicillin-Resistant Staphylococcus aureus/drug effects , Polysorbates/therapeutic use , Soybean Oil/therapeutic use , Staphylococcal Infections/drug therapy , Wound Infection/drug therapy , Animals , Anti-Bacterial Agents/pharmacology , Benzalkonium Compounds/pharmacology , Cytokines/analysis , Drug Combinations , Female , Humans , Mice , Microbial Sensitivity Tests , Polysorbates/pharmacology , Soybean Oil/pharmacology , Staphylococcal Infections/microbiology , Staphylococcal Infections/pathology , Swine , Wound Infection/microbiology , Wound Infection/pathology
7.
Mil Med ; 181(5 Suppl): 259-64, 2016 05.
Article in English | MEDLINE | ID: mdl-27168582

ABSTRACT

Despite advances in antimicrobial therapies, wound infection remains a global public health concern. We aimed to formulate and assess various nanoemulsions (NEs) for potential effectiveness as stable antimicrobial agents suitable for topic application. A total of 106 NEs were developed that varied with respect to nonionic and cationic surfactants. Stability testing demonstrated that the NEs tested are broadly stable, with 97/106 formulations passing 2-week stability tests. Two NEs, NB-201 and NB-402, were selected to test antimicrobial activity in a wound model in mice. Skin abrasion wounds were infected with Staphylococcus aureus followed by NE treatment. Infected skin was then evaluated by measuring colony forming units. NB-201 reduced median bacterial counts by 4 to 5 log compared to animals treated with saline, whereas NB-402 reduced bacterial counts by 2 to 3 log. Additional stability tests on NB-201 demonstrated that NB-201 is stable in the presence of human serum, and is stable for at least 6 months at 5°C, 25°C, and 40°C. Finally, in in vitro studies, NB-201 was found to be effective against S. aureus at a higher dilution than the commercially available silver sulfadiazine. Altogether these results demonstrate that NB-201 is a stable and effective topical antimicrobial for the treatment of S. aureus.


Subject(s)
Benzalkonium Compounds/pharmacology , Cetylpyridinium/pharmacology , Poloxamer/pharmacology , Polysorbates/pharmacology , Soybean Oil/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Animals , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/pharmacology , Anti-Infective Agents, Local/therapeutic use , Benzalkonium Compounds/administration & dosage , Benzalkonium Compounds/therapeutic use , Cetylpyridinium/administration & dosage , Cetylpyridinium/therapeutic use , Drug Combinations , Mice , Models, Animal , Poloxamer/administration & dosage , Poloxamer/therapeutic use , Polysorbates/administration & dosage , Polysorbates/therapeutic use , Silver Sulfadiazine/administration & dosage , Silver Sulfadiazine/pharmacology , Silver Sulfadiazine/therapeutic use , Soybean Oil/administration & dosage , Soybean Oil/therapeutic use , Wound Infection/drug therapy , Wound Infection/prevention & control
8.
Cutan Ocul Toxicol ; 35(1): 8-12, 2016 Mar.
Article in English | MEDLINE | ID: mdl-25597371

ABSTRACT

PURPOSE: To compare the rate of corneal epithelial healing and ocular tolerability following pterygium surgery between gatifloxacin and moxifloxacin. METHODS: In this double masked, prospective, controlled study 40 patients were randomized to receive prophylactic topical gatifloxacin 0.3% or moxifloxacin 0.5% following pterygium surgery. Patients were examined on days 1, 3, 7 and 21 post-operatively or until complete corneal epithelial healing. The primary outcome measure was the area of corneal epithelial defect during the post-operative period. Patients graded post-operative ocular pain, foreign body sensation, tearing, general burning sensation and burning sensation post-antibiotic drops instillation on a scale of 1-5. Conjunctival hyperemia and superficial punctate keratopathy (SPK) were measured on a scale of 0-3. RESULTS: No significant differences between groups were found in terms of corneal epithelial defect percentage over time (p = 0.989) and there was no significant difference between groups on each of the post-operative days. No significant differences were noted in terms of post-operative ocular pain, foreign body sensation, tearing, general burning sensation, burning sensation post-antibiotic drops instillation, conjunctival hyperemia and SPK. CONCLUSIONS: Gatifloxacin and moxifloxacin showed equivalent results in terms of corneal epithelial healing and ocular tolerability following pterygium surgery. This study suggests that there was no apparent added epithelial toxicity due to the presence of benzalkonium chloride in the gatifloxacin preparation when compared to moxifloxacin.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Epithelium, Corneal/drug effects , Fluoroquinolones/therapeutic use , Pterygium/surgery , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Benzalkonium Compounds/therapeutic use , Double-Blind Method , Female , Fluoroquinolones/adverse effects , Gatifloxacin , Humans , Male , Middle Aged , Moxifloxacin , Preservatives, Pharmaceutical/therapeutic use , Pterygium/drug therapy
9.
Poult Sci ; 92(10): 2560-6, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24046401

ABSTRACT

Lots of microorganisms exist in layer houses can cause bird diseases and worker health concerns. Spraying chemical disinfectants is an effective way to decontaminate pathogenic microorganisms in the air and on surfaces in poultry houses. Slightly acidic electrolyzed water (SAEW, pH 5.0-6.5) is an ideal, environmentally friendly broad-spectrum disinfectant to prevent and control bacterial or viral infection in layer farms. The purpose of this work was to investigate the cleaning effectiveness of SAEW for inactivating the microbes in layer houses. The effect of SAEW was evaluated by solid materials and surface disinfection in a hen house. Results indicate that SAEW with an available chlorine concentration of 250 mg/L, pH value of 6.19, and oxygen reduction potential of 974 mV inactivated 100% of bacteria and fungi in solid materials (dusts, feces, feather, and feed), which is more efficient than common chemical disinfectant such as benzalkonium chloride solution (1:1,000 vol/vol) and povidone-iodine solution (1:1,000 vol/vol). Also, it significantly reduced the microbes on the equipment or facility surfaces (P < 0.05), including floor, wall, feed trough, and water pipe surfaces. Moreover, SAEW effectively decreased the survival rates of Salmonella and Escherichia coli by 21 and 16 percentage points. In addition, spraying the target with tap water before disinfection plays an important role in spray disinfection.


Subject(s)
Chickens , Disinfectants/therapeutic use , Disinfection , Escherichia coli Infections/veterinary , Poultry Diseases/prevention & control , Salmonella Infections, Animal/prevention & control , Water/chemistry , Animal Husbandry , Animals , Benzalkonium Compounds/therapeutic use , Electrolysis/veterinary , Escherichia coli/drug effects , Escherichia coli Infections/microbiology , Escherichia coli Infections/prevention & control , Female , Housing, Animal , Poultry Diseases/microbiology , Povidone-Iodine/therapeutic use , Salmonella/drug effects , Salmonella Infections, Animal/microbiology , Water/administration & dosage
10.
Zhonghua Yan Ke Za Zhi ; 47(2): 101-4, 2011 Feb.
Article in Chinese | MEDLINE | ID: mdl-21426837

ABSTRACT

Long term use of topical anti-glaucoma drugs has been shown to induce chronic conjunctivitis, superficial punctate keratitis (SPK) and dry eye symptom. Under these conditions, a loss of goblet cells in conjunctiva, epithelial squamous metaplasia and apoptosis were morphologically revealed. Benzalkonium Chloride (BKC), a most frequently used preservative in eye drops, has been found to be an important factor causing ocular surface damage. Furthermore, a big challenge for ophthalmologists is that toxic damage of medication to ocular surface tissues is mild, poor specificity, and delayed manifestation in patients, especially when coexisting with other ocular surface diseases. Impairment of ocular surface tissues greatly impacts the life quality of patients and subsequently influences compliance with glaucoma therapy. This paper emphasizes to take measures to prevent ocular surface tissue damage resulted from chronic use of topical anti-glaucoma drugs and further discusses the treatment strategy. Effective and long-lasting action drugs should always be selected for glaucomatous patients in order to decrease the frequency of topical instillation or at a more expensive medication, a fixed combination formula can be considered for glaucoma therapy. An early surgery or laser treatment is also proposed for the patients who require an IOP reduction with an existing ocular surface impairment. Future investigation and development of new medications with long-term efficacy and appropriate BKC are suggested and preservative-free or drugs with new preservative materials recommended.


Subject(s)
Benzalkonium Compounds/adverse effects , Conjunctivitis/chemically induced , Glaucoma/drug therapy , Ophthalmic Solutions/adverse effects , Benzalkonium Compounds/therapeutic use , Dry Eye Syndromes/chemically induced , Humans
11.
Adv Ther ; 26(4): 447-54, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19381523

ABSTRACT

INTRODUCTION: Antibacterial activity of ophthalmic fourth-generation fluoroquinolones has traditionally been evaluated by comparing only their active ingredients, gatifloxacin and moxifloxacin. However, ophthalmic formulations of fourth-generation fluoroquinolones differ in terms of the inclusion of preservatives. While gatifloxacin ophthalmic solution 0.3% (Zymar; Allergan, Inc., Irvine, CA, USA) contains 0.005% benzalkonium chloride (BAK), moxifloxacin ophthalmic solution 0.5% (Vigamox; Alcon Laboratories, Inc., Fort Worth, TX, USA) is preservative-free. Recent studies have demonstrated that the presence of BAK dramatically affects the antibacterial activity of the ophthalmic formulation of gatifloxacin. This study was designed to compare the kill rates of ophthalmic solutions of fourth-generation fluoroquinolones against isolates of common ocular bacterial pathogens. METHODS: Approximately 5.6 log(10) colony-forming units (CFU)/mL of Haemophilus influenzae (n=1), Streptococcus pneumoniae (n=1), Staphylococcus aureus (n=2), methicillin-resistant Staphylococcus aureus (MRSA) (n=4), methicillinresistant Staphylococcus epidermidis (MRSE) (n=4), and fluoroquinolone-resistant S. epidermidis (n=1) were incubated with ophthalmic solutions of either gatifloxacin or moxifloxacin. Viable bacteria were quantified at specific time points up to 60 minutes. RESULTS: Gatifloxacin 0.3% completely eradicated H. influenzae and Strep. pneumoniae in 5 minutes, one of two S. aureus isolates in 15 minutes, and the other S. aureus isolate in 60 minutes. Gatifloxacin 0.3% completely killed all MRSA, MRSE, and fluoroquinolone-resistant S. epidermidis isolates in 15 minutes. Moxifloxacin 0.5% completely eradicated Strep. pneumoniae and one of four MRSA isolates in 60 minutes. All other isolates incubated with moxifloxacin 0.5% retained viable bacteria ranging from 1.8 to 4.4 log(10) CFU/mL. CONCLUSIONS: The ophthalmic solution of gatifloxacin 0.3% eradicated bacteria that frequently cause postoperative ocular infections substantially faster than did the ophthalmic solution of moxifloxacin 0.5%.


Subject(s)
Anti-Infective Agents/therapeutic use , Aza Compounds/therapeutic use , Eye Infections, Bacterial/microbiology , Fluoroquinolones/therapeutic use , Ophthalmic Solutions/therapeutic use , Quinolines/therapeutic use , Anti-Infective Agents/chemistry , Aza Compounds/chemistry , Benzalkonium Compounds/therapeutic use , Colony Count, Microbial , Drug Evaluation, Preclinical , Drug Resistance, Bacterial , Endophthalmitis/microbiology , Eye Infections, Bacterial/prevention & control , Fluoroquinolones/chemistry , Gatifloxacin , Haemophilus influenzae/drug effects , Humans , Keratitis/microbiology , Moxifloxacin , Ophthalmic Solutions/chemistry , Postoperative Complications/microbiology , Preservatives, Pharmaceutical/therapeutic use , Quinolines/chemistry , Staphylococcus aureus/drug effects , Staphylococcus epidermidis/drug effects , Streptococcus pneumoniae/drug effects , Time Factors
12.
rev. viernes med ; 32(5): 7-15, abr. 2008. tab, graf
Article in Spanish | LIPECS | ID: biblio-1112576

ABSTRACT

Objetivo: demostrar que la asepsia con cloruro de benzalconio es más efectiva que el uso de agua y jabón en la prevención de la onfalitis neonatal en el Hospital de Apoyo JAMO de Tumbes durante el período enero a abril del 2006. Métodos: estudio descriptivo, prospectivo, longitudinal y comparativo. Se incluyeron neonatos de ambos sexos, a término, de parto eutócico y cesárea, y se utilizó el muestreo no probabilístico de tipo accidental. El diseño fue de dos grupos, con sujetos aleatorizado y sólo con posprueba. Para la comparación de la efectividad del cloruro de benzalconio vs. El uso de agua y jabón se utilizaron las pruebas paramétricas Chi Cuadrado y t de Student. Resultados: ingresaron al estudio 84 neonatos; la mitad recibió asepsia con cloruro de benzalconio y el resto, con agua y jabón. Del total de la muestra, 82 neonatos no presentaron signos de onfalitis y sólo se evidenciaron dos casos, uno con cada tipo de antiséptico (2.4%). Sin embargo, no se encontró una relación significativa (p>0.05) entre la presencia de signos inflamatorios y el producto empleado para la asepsia. Asimismo, del total de la muestra (84 neonatos), cuatro presentaron la caída del cordón umbilical entre 3er y 5to día (uno con cloruro de benzalconio y tres con agua y jabón) mientras que a 78 neonatos se les desprendió el cordón umbilical entre el 6° y el 9° día y a dos neonatos pasados los diez días (un caso para cada antiséptico usado). Las pruebas estadísticas no mostraron relación significativa (p>0.05) entre el tiempo de caída del cordón umbilical y el tipo de antiséptico usado. Encontramos que al tasa de prevalencia de onfalitis fue de 2.38% y el tiempo promedio de aparición de los signos de onfalitis fue de cuatro días luego de utilizar ambos antisépticos.


Subject(s)
Male , Female , Humans , Infant, Newborn , Asepsis , Benzalkonium Compounds/therapeutic use , Umbilical Cord , Infections , Soaps/therapeutic use , Umbilicus , Water , Epidemiology, Descriptive , Longitudinal Studies , Prospective Studies
13.
Allergy ; 57(12): 1195-9, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12464050

ABSTRACT

BACKGROUND: A new technique, cutaneous field stimulation (CFS), which activates electrically unmyelinated C-fibers, is used to treat localized itch. Its action is similar to that of capsaicin, the pungent agent in hot peppers, which enhances delayed allergic reactions. The aim of the study was to investigate how experimental contact dermatitis responds to CFS. METHODS: Twelve patients with contact dermatitis in response to nickel were treated by CFS for 1 h each for four consecutive days. A flexible plate containing electrodes was applied to a test area on the upper arm and was stimulated by a constant current (0.8 mA). On the fifth day, patients were provoked by epicutaneous application of nickel sulfate (allergic contact dermatitis) and benzalkonium chloride (irritant contact dermatitis), and by intradermal tuberculin (delayed immunologic reaction). Twelve other patients with IgE-mediated allergy were treated by CFS on the lower arm for 1 h and were then pricked with histamine and allergen extracts (wheal volume was measured) and were tested using benzoic acid (nonimmunologic contact urticaria; closed test). Ten of these patients were also treated by CFS for four days, and experiments were performed on the fifth day. RESULTS: Test reactions to nickel, benzalkonium, and tuberculin were found to be unaffected by CFS treatment. Although allergic prick test reactions were enhanced (by 28%) after a single CFS treatment, the associated itch was significantly reduced both after single and repeated CFS treatments (by 65% and 38%, respectively). CONCLUSIONS: Repeated use of CFS to reduce itch has no adverse effects on contact dermatitis.


Subject(s)
Dermatitis, Allergic Contact/physiopathology , Dermatitis, Allergic Contact/therapy , Electric Stimulation Therapy , Nerve Fibers/physiology , Pruritus/physiopathology , Pruritus/therapy , Sensory Receptor Cells/physiology , Administration, Cutaneous , Adult , Aged , Anti-Infective Agents, Local/adverse effects , Anti-Infective Agents, Local/therapeutic use , Antifungal Agents/adverse effects , Antifungal Agents/therapeutic use , Benzalkonium Compounds/adverse effects , Benzalkonium Compounds/therapeutic use , Benzoic Acid/adverse effects , Benzoic Acid/therapeutic use , Cross Reactions/drug effects , Dermatitis, Irritant/etiology , Drug Eruptions/etiology , Female , Humans , Hypersensitivity, Immediate/physiopathology , Hypersensitivity, Immediate/therapy , Male , Middle Aged , Nickel/adverse effects , Nickel/therapeutic use , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/therapeutic use , Skin Tests , Treatment Outcome , Tuberculin/drug effects , Urticaria/chemically induced
14.
Clin Orthop Relat Res ; (329): 255-62, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8769460

ABSTRACT

This investigation seeks to determine whether surfactants or detergents can be used to clean and disinfect orthopaedic wounds with implanted hardware. Thus, a stepwise investigation of biocompatible surfactants and detergents was performed to identify an irrigation agent for disinfecting orthopaedic wounds. Bacterial adhesions assays, irrigation studies, and bactericidal assays determined that benzalkonium chloride showed the greatest efficacy. Testing involved stainless steel screws colonized with a preformed biofilm of Staphylococcus epidermidis, Staphylococcus aureus, or Pseudomonas aeruginosa, which were immersed in benzalkonium chloride solutions for various time intervals under static conditions. After 10 minutes, benzalkonium chloride achieved a minimum 4 log kill (10,000-fold) for all 3 strains of bacteria. Additional studies demonstrated that the high mechanical energy of jet irrigation improved the disinfecting properties of this agent. With jet lavage, both 1:1000 and 1:5000 concentrations of benzalkonium chloride achieved a minimum 2 log kill (100-fold) for all 3 bacteria. The results or this study suggest that at tissue compatible concentrations, benzalkonium chloride has significant disinfection properties for in vitro colonized orthopaedic devices, and these properties may be enhanced via jet lavage.


Subject(s)
Anti-Infective Agents, Local/therapeutic use , Benzalkonium Compounds/therapeutic use , Disinfection , Prostheses and Implants/microbiology , Biofilms , Humans , Microbial Sensitivity Tests , Oleic Acid , Oleic Acids/therapeutic use , Staphylococcus epidermidis , Surface-Active Agents , Therapeutic Irrigation
15.
Article in German | MEDLINE | ID: mdl-9272987

ABSTRACT

A comparative study involving 50 patients of both genders was conducted in order to determine the effect of dequalinium chloride/benzalconium chloride mouthrinse (Dequonal), and of a preparation of herbal essences (Parodontax) on gingival health. Each of the mouthrinses was used during four weeks by a group of 25 patients who were instructed to abstain from any other oral hygiene measure during this period. Approximal plaque index, sulcus bleeding index and saliva pH were significantly enhanced by both preparations. A slightly better effect shown by dequalinium chloride/benzalconium chloride was not significant.


Subject(s)
Anti-Infective Agents, Local/therapeutic use , Benzalkonium Compounds/therapeutic use , Dentifrices/therapeutic use , Dequalinium/therapeutic use , Gingiva/drug effects , Mouthwashes/therapeutic use , Plant Extracts/therapeutic use , Sodium Bicarbonate/therapeutic use , Adult , Complex Mixtures , Drug Combinations , Drug Evaluation , Female , Humans , Hydrogen-Ion Concentration , Male , Quinolinium Compounds , Saliva/drug effects
16.
J Occup Med ; 27(10): 733-9, 1985 Oct.
Article in English | MEDLINE | ID: mdl-4067676

ABSTRACT

Hydrofluoric acid (HF) burns are characterized by progressive tissue necrosis and severe pain. Numerous topical treatments have been proposed, yet few have been studied experimentally. The present study was designed to examine the comparative efficacy of recommended treatments. Hair on the hind legs of rats was removed and 48 hours later 70% HF was applied. Calcium gluconate, Zephiran (benzalkonium chloride), A + D Ointment, aloe gel, and magnesium ointment were applied topically and burn development was monitored. Calcium gluconate significantly reduced burn size as early as one hour after application. Significant protection continued for seven days after the single application. The other treatments were not effective in decreasing or delaying HF burn development. The results indicated that calcium gluconate ointment was the most effective topical treatment for HF burns.


Subject(s)
Burns, Chemical/therapy , Hydrofluoric Acid/adverse effects , Skin/injuries , Aloe , Animals , Benzalkonium Compounds/therapeutic use , Calcium Gluconate/therapeutic use , Drug Combinations , First Aid , Gels , Magnesium Oxide/administration & dosage , Magnesium Sulfate/administration & dosage , Male , Ointments , Plants, Medicinal , Rats , Rats, Inbred Strains , Vitamin A , Vitamin D
SELECTION OF CITATIONS
SEARCH DETAIL